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Summary of Recent Advances 
Novel analytic methods are required to assimilate the large volumes of structural and bioassay data 
generated by combinatorial chemistry and high-throughput screening programmes in the 
pharmaceutical and agrochemical industries. This paper reviews recent work in visualisation and data 
mining that can be used to develop structure-activity relationships from such chemical/biological 
datasets. 
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Introduction 
The search for lead compounds in the pharmaceutical industry (and also in the agrochemical and 
related industries) has historically followed an inherently sequential process, in which individual 
compounds are synthesised and then tested for biological activity, with the results of such experiments 
being fed back to inform the selection of further molecules. Developments in combinatorial chemistry 
[1-5] and in high-throughput screening (HTS) [6-8] mean that such operations have been largely 
replaced by a massively parallel mode of processing, in which many thousands of molecules can be 
synthesised and tested at the same time. This has resulted in an explosion in the volume of data that is 
available for the identification of structure-activity relationships (SAR). Quantitative SARs, typically 
using physicochemical parameters or 3D molecular fields with statistical techniques such as multiple 
regression or principal components analysis, have been an important tool for medicinal chemists for 
many years. However, such methods are normally used for the detailed analysis of small numbers of 
structurally-related molecules, and are not applicable to the large, structurally heterogeneous datasets 
that characterise modern HTS systems. There is hence much current interest in novel soft-computing 
approaches that might be applicable to the analysis of such datasets, and we here review recent work 
in this area, focusing upon the use of visualisation and data mining techniques.  
Visualisation Techniques 
Information and data visualisation plays an important role in practically all areas of scientific research. 
Consequently, many visualisation techniques like scatter plots or histograms have been developed 
[9,10]. That these established, simple visualisation techniques can help to identify patterns also in 
large datasets is demonstrated nicely in an article by Hand et al. [11*]. However, very interesting 
developments have been made in information and data visualisation over the last years that are 
especially aimed at large datasets [12**,13]. A thorough introduction to this important field was 
recently published by Card et al. [12**], who provide a collection of important classic and cutting 
edge articles in this field.  
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With the increasing importance of high-throughput chemistry and screening, the consequent increase 
in data volume [14] requires more effective methods to visualise and structure data produced in 
research. In addition, the emerging consolidation of research data in chemical data warehouses [15] 
makes it now more feasible to mine these sources. However, only few applications in chemistry have 
appeared over the past years. It can however be expected that visualisation will have a major impact 
on drug discovery over the next years [16]. 
Two general purpose data visualisation programs will act as examples of what is currently possible. 
Spotfire [17,18] (Spotfire® is a product of Spotfire Inc., Cambridge, MA, USA) is probably one of the 
best-known data visualisation and mining programs. Although it only provides basic graphs like 
scatter-plots, histograms and pie charts, its special features like database connectivity and interactive 
query devices make it a powerful tool for interactive visualisation and information analysis (see Figure 
1). Any change of the control elements is instantly executed and the user gets an immediate feedback. 
Another interesting visualisation program that has been applied to pharmaceutical research data is 
OmniViz Pro™ (OmniViz Pro is a trademark of OmniViz, Inc., Columbus, OH, USA). In contrast to 
Spotfire, this software is based on new methods for information visualisation developed by the 
Information Visualisation group of the Pacific Northwest National Laboratory (see 
http://multimedia.pnl.gov:2080/infoviz/). Figure 2 gives an example of the type of graphs that can be 
created with OmniViz Pro.  
In many cases, the available data are multidimensional. This is especially true for chemical 
compounds that can numerically be represented either by fingerprints or a set of descriptor values. In 
order to explore multidimensional data, it is necessary to map the data points into a 2- or 3-
dimensional space. This mapping is frequently called non-linear mapping. The aim of non-linear 
mapping is in most cases to preserve neighbouring properties, so that data points that are close 
together in the multidimensional space will be close together in the low-dimensional space. A variety 
of methods have been used over the last years in chemistry for the visualisation of databases [19], in 
diversity analysis [20,21] and for the analysis of structure-activity relationships [22,23]. 
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An established method for non-linear mapping is multidimensional scaling [24]. Principal component 
analysis or singular value decomposition can be used to get an initial estimate for the low dimensional 
representation of data points. In a second step, this projection is improved by optimising the data point 
separation in the low-dimensional space so that they resemble the distances of the data points in the 
high-dimensional space better. The quality of the mapping is measured by using the Sammon’s stress 
function or a variation thereof. Clark et al. [25*] proposed a particularly interesting modification of 
the original stress function. They observed that when mapping chemical structures based on 
fingerprints, the local similarity is not well preserved. This is due to the fact that the similarity 
measure used is an insufficient measure of dissimilarity. The suggested modification of the stress 
function ignores contributions of compounds with similarity smaller than a given value. The mapping 
obtained with the modified version clearly shows a more pronounced clustering of similar compounds.  
Unfortunately, multidimensional scaling is not well suited for large datasets, as the method scales 
quadratically with the number of data points. A significant improvement compared to conventional 
methods was achieved by Xie et al. [26], who applied the truncated-Newton optimisation method to 
improve the initial mapping obtained from singular value decomposition. They were able to 
demonstrate that the truncated-Newton optimisation can be up to 100 times faster than using the 
steepest descent method for optimisation. The approach is however not suitable for sets of several 
thousand data points.  
A variety of different approaches were used to apply neural nets for non-linear mapping. The 
advantage of neural nets is that they can be used to predict positions of new data points in the low-
dimensional space. A number of studies have used self-organising maps [27*] to visualise and analyse 
the diversity of databases [19,22,23]. It is also possible to use a multi-layer back-propagation neural 
net with n input and m output neurons (m=2,3). The output of the neural net for each output can be 
used as its m lower-dimensional co-ordinates [28]. Izrailev and Agrafiotis modified this method [29*]. 
Instead of using the full dataset, they suggest to train a feed-forward neural network to learn the 
projection obtained from conventional non-linear mapping of a subset of all data. The trained network 
can subsequently be used to project the whole compounds set. In an example of a combinatorial 
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library containing 57498 compounds, a subset of only 100 compounds (0.2 %) was already sufficient 
to generate a reasonable map of the whole dataset. Another approach uses a neural net with n neurons 
in the input and output layer and several middle layers. One of the hidden layers has m neurons. The 
net is trained to reproduce the input variables at the output neurons. The reduced dimensionality 
representation of a compound can then be read out from the m neurons of the middle layer [30]. 
While the described non-linear mapping techniques try to preserve the neighbouring relationship, the 
generated map might not necessarily be the best mapping if the aim is to visualise a classification. The 
classification mapping methods proposed by Su et al. [31*] aim to achieve this. The examples 
demonstrate that the techniques are able to give a qualitative or semi-quantitative picture.  
Probably the most important problem during lead optimisation in drug discovery is to determine SAR 
information. While it is quite feasible to develop this SAR knowledge for small numbers of 
compounds manually, it is necessary to automate this process for large datasets. The aim is to identify 
sets of similar compounds that have a common structure and show a systematic variation in one part 
(e.g. a substituent, a spacer or a ring system). Therefore, it may be interesting to compare one 
particular compound to a variety of other compounds in the dataset, to visualise the common features, 
and hence the potential pharmacophore patterns, that are present.  
Sheridan and Miller looked at recurrent topological substructures [32*]. They compare the structures 
of pairs of compounds and determine all common, possibly disconnected substructures. These 
substructures are scored and the highest scoring common substructure determined. This approach 
allows identifying 2D pharmacophores for a set of compounds. Another approach based on maximum 
common substructures is used by Distill (Distill is a trademark of Tripos Inc., St. Louis, MO, USA). 
This program develops a hierarchical organisation of compounds using maximum common 
substructures. The approach is however limited by the fact that there is only one classification tree for 
the structures created. This means that only one of all possible groupings of compounds can be 
explored, which will limit the SAR information that could be extracted from a set of compounds. 
Instead of using only a tree, the program LeadPharmer (LeadPharmer is a trademark of BioReason 
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Inc., Santa Fe, NM, USA) constructs ‘phylogenetic-like groupings’ of possible substructures [33-35]. 
The term ‘phylogenetic-like groupings’ was chosen to indicate that substructures are related. The 
determined substructures are used to assign compounds to different classes. It is possible that a 
compound can be assigned to more than one class. Using available activity information, interesting 
classes can be identified and the effect of structural variations on activity studied.  
One drawback of the approaches mentioned so far is that the construction of the tree classification can 
be a quite time-consuming process. The program LeadScope (LeadScope is a trademark of LeadScope 
Inc., Columbus, OH, USA) tries a different approach [36*]. The program does not construct possible 
substructures for a number of given compounds, but uses a set of predefined structure fragments (large 
taxonomy of familiar structural features such as functional groups, aromatics, and heterocycles) to 
classify the compounds. Therefore, compounds can be assigned to more than one group depending on 
the structural fragments they contain. The compound classification can be used to explore structure 
activity relationships in a dataset and search other databases for related structures (see Figure 3). 
Data Mining Techniques 
Visualisation enables a chemist to interact directly with sets of compounds, but can prove difficult 
when very many data points need to be considered. Data mining methods, which seek to identify 
meaningful inter-variable relationships in large, multidimensional datasets, are now being used in a 
wide range of subject domains, and it is hardly surprising that several of these methods have been used 
to investigate SARs. Three good general sources on data mining methods are the KDNUGGETS Web 
site (see URL http://www.kdnuggets.com), and the classic texts by Mitchell [37*] and by Duda and 
Hart [38*]. The basic problem addressed by all of these methods is that of classification: given a set of 
molecules for which the activity (or inactivity) is known (the training set), derive a rule that will 
enable new molecules (the test set) to be classified into the predicted-active or predicted-inactive 
classes. Training data can be generated internally from ongoing lead-discovery programmes or from 
publicly available files such as the MACCS Drug Data Report (MDDR), Available Chemicals 
Directory (ACD) and Standard Drug File databases; the resulting classifications can then be used to 
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guide the selection of new molecules for synthesis and testing. Thus far, chemical applications have 
involved the following principal approaches: statistical criteria, decision trees and neural networks.  
Medicinal chemists have known for many years that certain types of molecule are unlikely to possess 
the characteristics necessary for a successful drug: they may be too large to pass the blood-brain 
barrier, they may be insoluble, they may contain toxic or highly reactive functionality, etc. Attempts to 
quantify such characteristics started with Lipinski’s ‘Rule of Five’ and there have been several, more 
recent statistical analyses of sets of drug molecules (e.g., [39,40,41*]). A more sophisticated mode of 
analysis considers also sets of non-drug (or, more usually, presumed non-drug) molecules, this 
allowing the identification of rules that can be used to assess the ‘drug-likeness’ or ‘drugability’ of 
molecules. An obvious starting point is the distribution of global molecular properties in sets of drug 
and non-drug molecules. This approach was first studied by Gillet et al. [42**], using the distributions 
of molecular weight, numbers of rotatable bonds, numbers of aromatic rings and of hydrogen bond 
donors and acceptors, CLOGP and the 2Kα shape index. Here, the distributions for the value of some 
property in the drug and non-drug molecules is processed by a genetic algorithm (GA) [43] to produce 
a bioactivity profile, a set of weights that maximise the separation between the distributions for the 
two classes of molecule; the profiles, are then applied to the property values for test-set compounds so 
as to obtain a ranking of them in decreasing order of predicted drug-likeness. Gillet et al. subsequently 
described the use of the profiles in a GA for selecting combinatorial libraries of structurally diverse, 
drug-like molecules [44]; an analogous compound selection procedure has been reported by Sadowski 
[45] and there is now an extensive literature on the inclusion of drug-likeness in library design 
procedures [46-49]. A very similar set of global molecular properties has been studied by Oprea in a 
detailed analysis of several publicly-available datasets [50**], this analysis resulting in the 
specification of rules for compound-selection that are noticeably more precise than the original Rule of 
Five.  
Statistical analyses of the presence of fragment substructures in active and inactive molecules provides 
a simple, and convenient alternative to the use of property information. Such approaches were first 
described almost three decades ago but current requirements for effective compound-selection 
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procedures has resulted in a surge of interest (se, e.g., [36*,51-53]). Similar approaches can be used to 
highlight substructures that are undesirable for drug activity (e.g., on grounds of toxicity or unwanted 
reactivity) [41*,54*]. 
Neural networks have been applied to a wide range of chemical problems [55**] and they were one of 
the first such techniques to be applied to drugability studies, the two papers by Ajay et al. [56**] and 
by Sadowski and Kubinyi [57**] appearing contemporaneously with the GA-based approach of Gillet 
et al. [42**]. Here, the network is trained using sets of drugs and non-drugs, and a scoring threshold 
derived that can maximally discriminate between the two classes; test molecules can then be classified 
by calculating the score when they are presented to the network. Work in this area is exemplified by 
the recent study of Frimurer et al. [58*]. These authors used sets of molecules from the MDDR and 
ACD databases to exemplify drugs and non-drugs, with each molecule represented by normalised 
counts of the numbers of CONCORD atom-types present. These representations were input to a 
multilayered feed-forward neural network which, after appropriate training, was able to achieve a 
success rate of 88% in classifying MDDR and ACD compounds that had not been involved in the 
training; importantly, when used in a predictive manner, the network was able to identify drug-like 
molecules noticeably different from those obtained from conventional 2D similarity searches. 
Sadowski discusses the use of a similar neural-network system to discriminate between crop-
protecting and non crop-protecting compounds [45]. 
Decision trees provide an alternative classification tool. Here, the root of the tree represents an entire 
dataset, and this is subdivided into two (or more) subsets depending on the value of some splitting 
criterion. Various types of criteria can be used, such as the presence or absence of a particular 
substructural feature or a CLOGP value lying within a particular range. The potential splitting criteria 
are scored in some way, and the most advantageous chosen to split the dataset; the procedure is then 
repeated on the resulting sub-sets, and continued until some termination condition is satisfied. Several 
different splitting criteria and scoring schemes have been described [37*]. Decision trees were first 
used in drugability studies by Ajay et al. [56**]: these authors used the well-known C4.5 program 
(which employs an entropy-based scoring function) but who found that the resulting trees performed 
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less well than neural networks. More recently, however, Wagener and van Geerestein [59**] have 
used the successor program, C5.0, to distinguish between drug and non-drug compounds with a 
substantial measure of success on both public and corporate datasets. The most widely-used decision 
tree procedure for chemical applications has been the recursive partitioning approach, which uses a 
modified t-test for scoring potential splits. This approach has been popularised by Rusinko and co-
workers, who have used it not only to analyse 2D fragment substructural data [60**] but also to 
suggest 3D pharmacophores [61,62]. Other recent examples of the use of recursive partitioning are 
provided by Cho et al. [63] and by Miller [64*]. Decision trees have the advantage over neural 
networks that they provide explicit, readily comprehensible sets of rules for discussion with medicinal 
chemists [59**], although Walters and Murcko believe that they are susceptible to over-training, 
producing classification rules with little predictive power [65]. Mello and Brown [66] have criticised 
them for assigning test data to just a single class, and have thus developed a hybrid approach that uses 
the feature-selection capabilities of recursive partitioning as the input to a Bayesian inference network, 
while Miller has combined recursive partitioning with k-nearest neighbour searching [64*]. Finally, 
Jones-Hertzog et al. [67*] describe the use of recursive partitioning to support a sequential HTS 
analysis of 14 G-protein-coupled receptor targets; other examples of data mining in sequential 
screening programmes are described by Stanton et al. [68] and Engels et al. [69*], using nearest 
neighbour and cluster analysis. 
Drugability-based filtering is now common. That said, it must be emphasised that such schemes are 
still at a very early stage of development: they can often provide erroneous classifications if used 
without care [70], and they are arguably focused too much on known drugs rather than on the lead 
compounds that are the principal outputs of screening programmes [71*]. In addition, many of the 
reported studies thus far have focused on the difference between drugs and nondrugs; however, the 
same basic techniques can often be applied to the analysis of molecules from a particular therapeutic 
class if required [39,44,53,58*,72].   
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Conclusions 
This brief review has highlighted some of the soft computing methods that are now being applied to 
the analysis of the structure-activity relationships present in HTS datasets. However, there are many 
other methods that have already been, or could be, applied to such problems: examples include ant-
based computation [73,74], evolutionary Kohonen networks [27*], fuzzy clustering [23], support 
vector machines [75] and Bayesian learning [66]. We believe that methods such as these will prove 
invaluable in the analysis of the huge volumes of data that characterise modern pharmaceutical 
research, particularly when used in combination [76**.77**].  































Figure 1: A trellis display created using Spotfire. The four scatter plots compare activity data of 
compounds measured for two subtypes of a protein. In addition, the compounds were classified into 
four different structural classes. Each scatter plot shows the data points for one structural class. A 
comparison of the different scatter plots reveals interesting details. The compounds in class 3 are more 
selective for protein 1, whereas the compounds in class 4 are equipotent on both proteins. Compound 
class 2 shows no preference but two groups of compounds are clearly visible. A comparison of the 
structures in the different classes can reveal further information about the SAR. 
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Figure 2: OmniViz Pro™, from OmniViz, Inc. (Columbus, OH, USA) provides integrated analysis of 
text, numeric, categorical, and genomic sequence data within a visual Cognitive Analytical 
Environment™. Here, the software was used in an analysis of 1107 compounds with defined 
fingerprints that had been screened in 19 biological assays. 
In (a), the compounds are represented in a Galaxy™ view, a proximity map that shows how every 
record is related to every other record. In this map, the similarity is based on the fingerprints, 
providing a view of the chemical information space. Individual records (blue dots) represent each 
compound and the clusters of related compounds are evident (marked by circles). A separate Galaxy 
view in (b) shows the same compounds but with the similarity based on the biological activity profile 
(biological activity space). A cluster of compounds (lower right) was selected (highlighted yellow) in 
the biological activity space and the corresponding compounds were automatically highlighted in the 
structure-based Galaxy. The distribution of the compounds in the structure space indicates that most 
have similar fingerprint attributes (since they are located in close proximity), but a few are distant 
(e.g., two in the cluster at the bottom left). This suggests that an alternative set of structural attributes 
might create the same activity profile - suggesting a new class of structures to pursue. 
Courtesy of OmniViz Inc. 
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Figure 3: The screenshot of the LeadScope user interface shows a comparison of two projects in the 
histogram view. The left panel shows the structural feature hierarchy open to reveal a portion of the 
Heterocycles:quinoline branch with quinoline, 2-phenyl selected. The central graphic panel shows 
parallel histograms comparing the contents of two projects relative to the structural features; each 
histogram bar gives the frequency of the feature class plotted on a log scale. The right panel contains a 
series of the property filters, which can be adjusted to select compounds with properties in specific 
ranges.  
The database corresponding to the histogram on the left are compounds tested by the National Cancer 
Institute’s (NCI) Developmental Therapeutics Program for growth inhibition and cytotoxicity against 
a panel of 60 human cancer cell lines. The comparison database – corresponding to the histogram on 
the right – are compounds available from Maybridge Chemical Company Ltd [Trevillett, Tintagel, 
Cornwall PL34 OHW UK]. 
Histogram bars are colour-coded based on the difference, expressed in number of standard deviations, 
between the mean activity of the subset of compounds containing a structural feature from the mean 
activity of the full set. In this example, IC50 data for the SF-295 cell line from the CNS panel is used 
for the NCI dataset. This technique can be used to locate subsets with unusually high mean activity 
and then identify new members of the structural class available from a commercial source. 
Courtesy of LeadScope Inc. 
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